Cogent Biosciences, Inc. entered into exchange agreements with existing stockholders to exchange 8,300,000 shares of common stock for 8,300 shares of Series B Preferred Stock, increasing the authorized shares of Series B Preferred Stock from 12,280 to 20,580.